ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
To evaluate the outcome of a prednisolone and low dose methotrexate based protocol in Down syndrome children with ALL (DS-ALL) in an Asia-wide study. The treatment protocol was modified based upon backbone of Taiwan Pediatric Oncology Group (TPOG)-ALL protocol in which risk classification will be guided by level of flow minimal residual disease (MRD) instead.
Down Syndrome|Acute Lymphoblastic Leukemia|Childhood Cancer
DRUG: Daunorubicin|DRUG: Prednisolone|DRUG: Vincristine|DRUG: Epirubicin|DRUG: E-coli L-asparaginase|DRUG: 6-Mercaptopurine|DRUG: Methotrexate|DRUG: Hydrocortisone|DRUG: Cytarabine|DRUG: Cyclophosphamide
Event Free Survival, Percentage of patients who are event free at 5 years., Up to 5 years
Overall survival, Percentage of patients who survive at 5 years., Up to 5 years|Disease free survival, Percentage of patients who are leukemia free at 5 years., Up to 5 years|Induction failure, Percentage of patients who had failed induction., 5 weeks|Complete remission rate, Percentage of patients who had achieved complete remission at the end of induction., 5 weeks|Cumulative incidence of relapse, Up to 5 years|Incidence of treatment-related adverse events, Incidence of treatment-related infectious and metabolic complications (throughout various phases of study therapy) and secondary neoplasms., Up to 10 years|Flow MRD at day 15, To assess the prognostic value flow MRD level during induction for DS-ALL., At day 15 of induction therapy
To evaluate the outcome of a prednisolone and low dose methotrexate based protocol in Down syndrome children with ALL (DS-ALL) in an Asia-wide study. The treatment protocol was modified based upon backbone of Taiwan Pediatric Oncology Group (TPOG)-ALL protocol in which risk classification will be guided by level of flow minimal residual disease (MRD) instead.